Episurf Medical is planning the 300th surgery with its Episealer® personalized implant, to occur in coming weeks. This represents a doubling of the number of procedures performed as of mid-4Q16.
Episealer devices treat localized cartilage damage in the knee. The implants and surgical tools are approved under the CE Mark; in 2Q17, the company indicated that it was engaged in obtaining FDA’s views about classification and the regulatory requirements that may be applicable to the Episealer device.
Sources: Episurf Medical; ORTHOWORLD Inc.